Real-world data helps evaluate program outcomes beyond clinical trials, ensuring that support meets members' actual needs in diverse environments
Risk appears highest in patients with prior pancreatitis history or gallbladder disease
Understanding its action, efficacy data, safety considerations, and developmental status provides essential context for evaluating its role in contemporary metabolic disease management
They are not intended for diagnostic, therapeutic, or clinical use
Thanks to our own production and development within the European Union, our experts in nutrition and performance guarantee the quality of our products
We observed that 11.8% of tirzepatide-treated rs1800437-CC carrier individuals experienced vomiting, compared with 9.4% for semaglutide-treated people carrying the same genotype, although the difference was not significant ( P = 0.12, two-sample z -test